Kennedy Capital Management’s AbbVie ABBV Stock Holding History

Kennedy Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.3M	Sell	64,782 -198	-0.3%	-$42.6K	0.29%	107
2026 Q1	$14.1M	Buy	64,980 +2,249	+4%	+$499K	0.3%	112
2025 Q4	$14.3M	Sell	62,731 -236	-0.4%	-$53.8K	0.3%	116
2025 Q3	$14.6M	Sell	62,967 -24,196	-28%	-$4.93M	0.32%	96
2025 Q2	$16.2M	Sell	87,163 -11,991	-12%	-$2.23M	0.39%	65
2025 Q1	$20.8M	Sell	99,154 -8,984	-8%	-$1.75M	0.5%	36
2024 Q4	$19.2M	Buy	108,138 +12,675	+13%	+$2.33M	0.43%	38
2024 Q3	$18.9M	Buy	95,463 +14,509	+18%	+$2.71M	0.42%	42
2024 Q2	$13.9M	Buy	80,954 +18,448	+30%	+$3.06M	0.3%	91
2024 Q1	$11.4M	Buy	62,506 +61,053	+4,202%	+$10.5M	0.23%	142
2023 Q4	$225K	Buy	1,453 +10	+0.7%	+$1.46K	﹤0.01%	671
2023 Q3	$215K	Buy	+1,443	New	+$212K	0.01%	652
2023 Q2	–	Sell	-1,343	Closed	-$214K	–	666
2023 Q1	$214K	Buy	1,343 +8	+0.6%	+$1.22K	0.01%	601
2022 Q4	$216K	Buy	+1,335	New	+$205K	0.01%	594
2022 Q3	–	Sell	-1,664	Closed	-$255K	–	606
2022 Q2	$255K	Hold	1,664	–	–	0.01%	577
2022 Q1	$270K	Hold	1,664	–	–	0.01%	577
2021 Q4	$225K	Buy	+1,664	New	+$197K	﹤0.01%	601

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Kennedy Capital Management's ABBV Position: Q2 2026 in Review

Kennedy Capital Management reduced its AbbVie (ABBV) stake by 0.3% in Q2 2026, selling an estimated $42.6K and leaving 64,782 shares worth $16.3M. The position accounts for 0.29% of the portfolio, ranked #107.

Kennedy Capital Management first reported a position in ABBV in Q4 2021 and has held it in 17 quarters since. The position peaked at $20.8M in Q1 2025. 4,190 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Kennedy Capital Management held 64,782 shares of AbbVie worth $16.3M as of Q2 2026.
Kennedy Capital Management sold 198 AbbVie shares in Q2 2026, an estimated $42.6K.
AbbVie made up 0.29% of Kennedy Capital Management's portfolio in Q2 2026, its #107 holding.
Kennedy Capital Management first reported a position in AbbVie in Q4 2021 and has held it in 17 quarters since.
Kennedy Capital Management's AbbVie position peaked at $20.8M in Q1 2025.
4,190 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.